Related Experiment Video
Updated: Oct 11, 2025
07:22
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
6.6K
Fostemsavir: a first-in-class HIV-1 attachment inhibitor
Philip M Grant1, Michael J Kozal
1Stanford University 300 Pasteur Drive, Stanford, California, USA.
Current Opinion in HIV and AIDS
|December 6, 2021
Summary
Fostemsavir, a new HIV-1 attachment inhibitor, is effective and well-tolerated for multidrug-resistant HIV-1. It helps heavily treatment-experienced patients achieve virologic suppression with optimal background therapy.
Area of Science:
- Virology
- Pharmacology
- Immunology
Background:
- Human Immunodeficiency Virus type 1 (HIV-1) infection remains a global health challenge.
- Multidrug-resistant HIV-1 strains necessitate novel therapeutic strategies.
- Antiretroviral therapy has significantly improved outcomes but faces challenges with resistance.
Purpose of the Study:
- To review the pharmacology, efficacy, tolerability, and resistance profile of fostemsavir.
- To evaluate fostemsavir's role in treating multidrug-resistant HIV-1.
- To discuss the implications of fostemsavir's approval for patient care.
Main Methods:
- Review of published literature on fostemsavir.
- Analysis of clinical trial data regarding fostemsavir's efficacy and safety.
- Examination of in vitro studies on fostemsavir's mechanism of action and resistance.
Main Results:
- Fostemsavir is an HIV-1 attachment inhibitor targeting gp120, preventing viral entry.
- It is well-tolerated and maintains virologic activity in patients with multidrug-resistant HIV-1.
- A majority of heavily treatment-experienced participants achieved virologic suppression with fostemsavir and optimal background therapy.
Conclusions:
- Fostemsavir's approval is a significant advancement for multidrug-resistant HIV-1 treatment.
- Its novel mechanism offers an option with no cross-resistance to existing antiretrovirals.
- Further research is needed to define the role of resistance testing and fostemsavir's use beyond salvage therapy.
Related Concept Videos
02:33Retroviruses
12.8K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.8K
01:29Subviral Agents
179
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
179
01:10Retrovirus Life Cycles
47.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
47.5K
01:31Immunoglobulin-like Cell Adhesion Molecules
3.5K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.5K